PGC-1α is responsible for survival of multiple myeloma cells under hyperglycemia and chemotherapy

Oncology Reports

Volumn 33, Issue 4, 2015, Pages 2086-2092

  Yu, Wen ^a   Cao, Dedong ^b   Zhou, Hao ^a   Hu, Yu ^a   Guo, Tao ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Bortezomib; Hyperglycemia; Multiple myeloma; PGC 1 ; Reactive oxygen species

Indexed keywords

BORTEZOMIB; CATALASE; DEXAMETHASONE; GLUTATHIONE PEROXIDASE 1; MANGANESE SUPEROXIDE DISMUTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; ANTIOXIDANT; GLUCOSE; GLUTATHIONE PEROXIDASE; PPARGC1A PROTEIN, HUMAN; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; FLOW CYTOMETRY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; MTT ASSAY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; DRUG EFFECTS; GENETICS; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CATALASE; CELL LINE, TUMOR; CELL SURVIVAL; GLUCOSE; GLUTATHIONE PEROXIDASE; HUMANS; HYPERGLYCEMIA; MULTIPLE MYELOMA; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84924874095     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3809     Document Type: Article

References (45)

1. Guglielmelli T and Palumbo A: Incorporating novel agents in the management of elderly myeloma patients. Curr Hematol Malig Rep 8: 261-269, 2013.
2. Palumbo A and Mina R: Management of older adults with multiple myeloma. Blood Rev 27: 133-142, 2013.
3. Chou YS, Yang CF, Chen HS, et al: Pre-existing diabetes mellitus in patients with multiple myeloma. Eur J Haematol 89: 320-327, 2012.
4. Issa ZA, Zantout MS and Azar ST: Multiple myeloma and diabetes. ISRN Endocrinol 2011: 815013, 2011.
5. Jung SH, Jang HC, Lee SS, et al: The impact of hyperglycemia on risk of severe infections during early period of induction therapy in patients with newly diagnosed multiple myeloma. Biomed Res Int 2014: 413149, 2014.
6. Ahmed YA and Eltayeb A: Clinical challenges: myeloma and concomitant type 2 diabetes. Int J Hematol Oncol Stem Cell Res 7: 34-41, 2013.
7. Wu W, Merriman K, Nabaah A, et al: The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer 111: 628-636, 2014.
8. Chiu BC, Gapstur SM, Greenland P, Wang R and Dyer A: Body mass index, abnormal glucose metabolism, and mortality from hematopoietic cancer. Cancer Epidemiol Biomarkers Prev 15: 2348-2354, 2006.
9. Baynes JW: Role of oxidative stress in development of complications in diabetes. Diabetes 40: 405-412, 1991.
10. Busik JV, Mohr S and Grant MB: Hyperglycemia-induced reactive oxygen species toxicity to endothelial cells is dependent on paracrine mediators. Diabetes 57: 1952-1965, 2008.
11. Zorov DB, Juhaszova M and Sollott SJ: Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev 94: 909-950, 2014.
12. Edeas M: Strategies to target mitochondria and oxidative stress by antioxidants: key points and perspectives. Pharm Res 28: 2771-2779, 2011.
13. Vurusaner B, Poli G and Basaga H: Tumor suppressor genes and ROS: complex networks of interactions. Free Radic Biol Med 52: 7-18, 2012.
14. Valle I, Alvarez-Barrientos A, Arza E, Lamas S and Monsalve M: PGC-1alpha regulates the mitochondrial antioxidant defense system in vascular endothelial cells. Cardiovasc Res 66: 562-573, 2005.
15. Nishikawa T, Edelstein D, Du XL, et al: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404: 787-790, 2000.
16. Finck BN and Kelly DP: PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 116: 615-622, 2006.
17. Cao D, Zhou H, Zhao J, et al: PGC-1? integrates glucose metabolism and angiogenesis in multiple myeloma cells by regulating VEGF and GLUT-4. Oncol Rep 31: 1205-1210, 2014.
18. St-Pierre J, Drori S, Uldry M, et al: Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127: 397-408, 2006.
19. Kong X, Wang R, Xue Y, et al: Sirtuin 3, a new target of PGC-1 alpha, plays an important role in the suppression of ROS and mitochondrial biogenesis. PLoS One 5: e11707, 2010.
20. Fujisawa K, Nishikawa T, Kukidome D, et al: TZDs reduce mitochondrial ROS production and enhance mitochondrial biogenesis. Biochem Biophys Res Commun 379: 43-48, 2009.
21. Zhang LN, Zhou HY, Fu YY, et al: Novel small-molecule PGC-1? transcriptional regulator with beneficial effects on diabetic db/db mice. Diabetes 62: 1297-1307, 2013.
22. Pearce EL, Walsh MC, Cejas PJ, et al: Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 460: 103-107, 2009.
23. Villarreal-Garza C, Shaw-Dulin R, Lara-Medina F, et al: Impact of diabetes and hyperglycemia on survival in advanced breast cancer patients. Exp Diabetes Res 2012: 732027, 2012.
24. Luo J, Chen YJ and Chang LJ: Fasting blood glucose level and prognosis in non-small cell lung cancer (NSCLC) patients. Lung Cancer 76: 242-247, 2012.
25. Friday E, Ledet J and Turturro F: Response to dexamethasone is glucose-sensitive in multiple myeloma cell lines. J Exp Clin Cancer Res 30: 81, 2011.
26. Scarpulla RC, Vega RB and Kelly DP: Transcriptional integration of mitochondrial biogenesis. Trends Endocrinol Metab 23: 459-466, 2012.
27. Sheean PM, Kilkus JM, Liu D, Maciejewski J and Braunschweig CA: Incident hyperglycemia, parenteral nutrition administration and adverse outcomes in patients with myeloma admitted for initial auto-SCT. Bone Marrow Transplant 48: 1117-1122, 2013.
28. McBrayer SK, Cheng JC, Singhal S, Krett NL, Rosen ST and Shanmugam M: Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy. Blood 119: 4686-4697, 2012.
29. Zhao Y, Butler EB and Tan M: Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 4: e532, 2013.
30. Gitenay D, Wiel C, Lallet-Daher H, et al: Glucose metabolism and hexosamine pathway regulate oncogene-induced senescence. Cell Death Dis 5: e1089, 2014.
31. Zhao Y, Liu H, Riker AI, et al: Emerging metabolic targets in cancer therapy. Front Biosci (Landmark Ed) 16: 1844-1860, 2011.
32. DeBerardinis RJ, Mancuso A, Daikhin E, et al: Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 104: 19345-19350, 2007.
33. Zhao Y, Altman BJ, Coloff JL, et al: Glycogen synthase kinase 3alpha and 3beta mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1. Mol Cell Biol 27: 4328-4339, 2007.
34. Danial NN, Gramm CF, Scorrano L, et al: BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 424: 952-956, 2003.
35. Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM and Thompson CB: Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor?independent survival. Mol Cell Biol 23: 7315-7328, 2003.
36. Mathupala SP, Ko YH and Pedersen PL: Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25: 4777-4786, 2006.
37. Gendron MC, Schrantz N, Metivier D, et al: Oxidation of pyridine nucleotides during Fas-and ceramide-induced apoptosis in Jurkat cells: correlation with changes in mitochondria, glutathione depletion, intracellular acidification and caspase 3 activation. Biochem J 353: 357-367, 2001.
38. Vu K, Busaidy N, Cabanillas ME, et al: A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 12: 355-362, 2012.
39. Puigserver P, Wu Z, Park CW, Graves R, Wright M and Spiegelman BM: A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92: 829-839, 1998.
40. Kang C and Li Ji L: Role of PGC-1? signaling in skeletal muscle health and disease. Ann NY Acad Sci 1271: 110-117, 2012.
41. Radak Z, Zhao Z, Koltai E, Ohno H and Atalay M: Oxygen consumption and usage during physical exercise: the balance between oxidative stress and ROS-dependent adaptive signaling. Antioxid Redox Signal 18: 1208-1246, 2013.
42. Wenz T: Regulation of mitochondrial biogenesis and PGC-1? under cellular stress. Mitochondrion 13: 134-142, 2013.
43. Salem AF, Whitaker-Menezes D, Howell A, Sotgia F and Lisanti MP: Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance. Cell Cycle 11: 4174-4180, 2012.
44. Tennakoon JB, Shi Y, Han JJ, et al: Androgens regulate prostate cancer cell growth via an AMPK-PGC-1?-mediated metabolic switch. Oncogene 33: 5251-5261, 2014.
45. Girnun GD: The diverse role of the PPAR? coactivator 1 family of transcriptional coactivators in cancer. Semin Cell Dev Biol 23: 381-388, 2012.